Ultomiris

Pharmacotherapeutic group: Immunosuppressants, complement inhibitors, ATC code: L04A J02 Mechanism of action Ravulizumab is a monoclonal antibody IgG 2/4K that specifically binds to the complement protein C5, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the membrane attack complex [MAC or C5b‑9]) and preventing the generation of the C5b‑9.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ Ravulizumab preserves the early components of complement activation that are essential for opsonisation of microorganisms and clearance of immune complexes. Pharmacodynamic effects Following ravulizumab treatment in both adult and paediatric complement inhibitor-naïve patients and eculizumab‑experienced patients with PNH in Phase 3 studies, immediate, complete and sustained inhibition of serum free C5 (concentration of < 0.5 µg/mL) was observed by the end of the first infusion and sustained throughout the entire 26‑week treatment period in all patients. Immediate and complete inhibition of serum free C5 was also observed in adult and paediatric patients with aHUS, in adult patients with gMG, and in adult patients with NMOSD by the end of the first infusion and throughout the primary treatment period. The extent and duration of the pharmacodynamic response in patients with PNH, aHUS, gMG, or NMOSD were exposure dependent for ravulizumab. Free C5 levels less than 0.5 µg/mL were correlated with maximal intravascular haemolysis control and complete terminal complement inhibition. In gMG, terminal complement activation leads to MAC deposition at the neuromuscular junction and impairment of neuromuscular transmission. In NMOSD, terminal complement activation leads to MAC formation and C5a-dependent inflammation, astrocyte necrosis, and damage to surrounding glial cells and neurons. Clinical efficacy and safety Paroxysmal nocturnal haemoglobinuria (PNH) The safety and efficacy of ravulizumab in adult patients with PNH were assessed in two open-label, randomised, active-controlled Phase 3 trials: • a complement inhibitor-naïve study in adult patients with PNH who were naïve to complement inhibitor treatment, • an eculizumab-experienced study in adult patients with PNH who were clinically stable after having been treated with eculizumab for at least the previous 6 months. Ravulizumab was dosed in accordance with the recommended dosing described in section 4.2 (4 infusions of ravulizumab over 26 weeks) while eculizumab was administered according to the approved dosing regimen of eculizumab of 600 mg every week for the first 4 weeks and 900 mg every 2 weeks (15 infusions over 26 weeks). Patients were vaccinated against meningococcal infection prior to or at the time of initiating treatment with ravulizumab or eculizumab or received prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination. There were no noteworthy differences in the demographic or baseline characteristics between the ravulizumab and eculizumab treatment groups in either of the Phase 3 studies. The 12‑month transfusion history was similar between ravulizumab and eculizumab treatment groups within each of the Phase 3 studies. Study in complement inhibitor-naïve adult patients with PNH (ALXN1210-PNH-301) The complement inhibitor-naïve study was a 26‑week, multicentre, open-label, randomised, active‑controlled, Phase 3 study conducted in 246 patients who were naïve to complement inhibitor treatment prior to study entry and was followed by a long-term extension period where all patients received ravulizumab. Eligible patients to enter this trial had to demonstrate high disease activity, defined as LDH level ≥ 1.5 × upper limit of normal (ULN) at screening along with the presence of 1 or more of the following PNH-related signs or symptoms within 3 months of screening: fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), anaemia (haemoglobin < 10 g/dL), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cell (pRBC) transfusion due to PNH. More than 80 % of patients in both treatment groups had a history of transfusion within 12 months of study entry. The majority of the complement inhibitor-naïve study population was highly haemolytic at baseline; 86.2 % of enrolled patients presented with elevated LDH ≥ 3 × ULN, which is a direct measurement of intravascular haemolysis, in the setting of PNH. Table 8 presents the baseline characteristics of the PNH patients enrolled in the complement inhibitor-naïve study, with no apparent clinically meaningful differences observed between the treatment arms. Table 8: Baseline characteristics in the complement inhibitor-naïve study Parameter Statistics Ravulizumab (N = 125) Eculizumab (N = 121) Age (years) at PNH diagnosis Mean (SD) Median Min, max 37.9 (14.90) 34.0 15, 81 39.6 (16.65) 36.5 13, 82 Age (years) at first infusion in study Mean (SD) Median Min, max 44.8 (15.16) 43.0 18, 83 46.2 (16.24) 45.0 18, 86 Sex (n, %) Male Female 65 (52.0) 60 (48.0) 69 (57.0) 52 (43.0) Pre-treatment LDH levels Mean (SD) Median 1633.5 (778.75) 1513.5 1578.3 (727.06) 1445.0 Number of patients with packed red blood cell (pRBC) transfusions within 12 months prior to first dose n (%) 103 (82.4) 100 (82.6) Units of pRBC transfused within 12 months prior to first dose Total Mean (SD) Median 925 9.0 (7.74) 6.0 861 8.6 (7.90) 6.0 Total PNH RBC clone size Median 33.6 34.2 Total PNH granulocyte clone size Median 93.8 92.4 Patients with any PNH conditions a prior to informed consent Anaemia Haematuria or haemoglobinuria Aplastic anaemia Renal failure Myelodysplastic syndrome Pregnancy complication Other b n (%) 121 (96.8) 103 (82.4) 81 (64.8) 41 (32.8) 19 (15.2) 7 (5.6) 3 (2.4) 27 (21.6) 120 (99.2) 105 (86.8) 75 (62.0) 38 (31.4) 11 (9.1) 6 (5.0) 4 (3.3) 13 (10.7) a Based on medical history. b “Other” as specified on case report form included thrombocytopenia, chronic kidney disease, and pancytopenia, as well as a number of other conditions. The coprimary endpoints were transfusion avoidance, and haemolysis as directly measured by normalisation of LDH levels (LDH levels ≤ 1 × ULN; the ULN for LDH is 246 U/L). Key secondary endpoints included the percent change from baseline in LDH levels, change in quality of life (FACIT‑Fatigue), the proportion of patients with breakthrough haemolysis and proportion of patients with stabilised haemoglobin. Ravulizumab was non-inferior compared to eculizumab for both coprimary endpoints, avoidance of pRBC transfusion per protocol-specified guidelines and LDH normalisation from day 29 to day 183, and for all 4 key secondary endpoints (Figure 1). Figure 1: Analysis of coprimary and secondary endpoints – full analysis set (complement inhibitor-naïve study) Note: The black triangle indicates the non-inferiority margins, and grey dots indicates point estimates. Note: LDH = lactate dehydrogenase; CI = confidence interval; FACIT = Functional Assessment of Chronic Illness Therapy. The final efficacy analysis for the study included all patients ever treated with ravulizumab (n=244) and had a median treatment duration of 1423 days. The final analysis confirmed that ravulizumab treatment responses observed during the Primary Evaluation Period were maintained throughout the duration of the study. Study in adult PNH patients previously treated with eculizumab (ALXN1210-PNH-302) The eculizumab-experienced study was a 26-week, multicentre, open-label, randomised, active‑controlled Phase 3 study conducted in 195 patients with PNH who were clinically stable (LDH ≤ 1.5 x ULN) after having been treated with eculizumab for at least the past 6 months and was followed by a long-term extension period where all patients received ravulizumab. PNH medical history was similar between ravulizumab and eculizumab treatment groups. The 12‑month transfusion history was similar between ravulizumab and eculizumab treatment groups and more than 87 % of patients in both treatment groups had not received a transfusion within 12 months of study entry. The mean total PNH RBC clone size was 60.05 %, mean total PNH granulocyte clone size was 83.30 %, and the mean total PNH monocyte clone size was 85.86 %. Table 9 presents the baseline characteristics of the PNH patients enrolled in the eculizumab-experienced study, with no apparent clinically meaningful differences observed between the treatment arms. Table 9: Baseline characteristics in the eculizumab-experienced study Parameter Statistics Ravulizumab (N = 97) Eculizumab (N = 98) Age (years) at PNH diagnosis Mean (SD) Median Min, max 34.1 (14.41) 32.0 6, 73 36.8 (14.14) 35.0 11, 74 Age (years) at first infusion in study Mean (SD) Median Min, max 46.6 (14.41) 45.0 18, 79 48.8 (13.97) 49.0 23, 77 Sex (n, %) Male Female 50 (51.5) 47 (48.5) 48 (49.0) 50 (51.0) Pre-treatment LDH levels Mean (SD) Median 228.0 (48.71) 224.0 235.2 (49.71) 234.0 Number of patients with pRBC/whole blood transfusions within 12 months prior to first dose n (%) 13 (13.4) 12 (12.2) Units of pRBC/whole blood transfused within 12 months prior to first dose Total Mean (SD) Median 103 7.9 (8.78) 4.0 50 4.2 (3.83) 2.5 Patients with any PNH conditions a prior to informed consent Anaemia Haematuria or haemoglobinuria Aplastic anaemia Renal failure Myelodysplastic syndrome Pregnancy complication Other b n (%) 90 (92.8) 64 (66.0) 47 (48.5) 34 (35.1) 11 (11.3) 3 (3.1) 4 (4.1) 14 (14.4) 96 (98.0) 67 (68.4) 48 (49.0) 39 (39.8) 7 (7.1) 6 (6.1) 9 (9.2) 14 (14.3) a Based on medical history. b “Other” category included neutropenia, renal dysfunction, and thrombopenia, as well as a number of other conditions. The primary endpoint was haemolysis as measured by LDH percent change from baseline. Secondary endpoints included the proportion of patients with breakthrough haemolysis, quality-of-life (FACIT‑Fatigue), transfusion avoidance (TA), and proportion of patients with stabilised haemoglobin. Ravulizumab was non-inferior compared to eculizumab for the primary endpoint, percent change in LDH from baseline to day 183, and for all 4 key secondary endpoints (Figure 2). Figure 2: Analysis of primary and secondary endpoints – full analysis set (eculizumab‑experienced study) Note: The black triangle indicates the non-inferiority margins, and grey dot indicates point estimates. Note: LDH = lactate dehydrogenase; CI = confidence interval. The final efficacy analysis for the study included all patients ever treated with ravulizumab (n=192) and had a median treatment duration of 968 days. The final analysis confirmed that ravulizumab treatment responses observed during the primary evaluation period were maintained throughout the duration of the study. Atypical haemolytic uremic syndrome (aHUS) Study in adult patients with aHUS (ALXN1210-aHUS-311) The adult study was a multicentre, single arm, Phase 3 study conducted in patients with documented aHUS who were naïve to complement inhibitor treatment prior to study entry and had evidence of thrombotic microangiopathy (TMA). The study consisted of a 26-week initial evaluation period and patients were allowed to enter an extension period for up to 4.5 years. A total of 58 patients with documented aHUS were enrolled. Enrolment criteria excluded patients presenting with TMA, due to a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency, Shiga toxin Escherichia coli related haemolytic uremic syndrome (STEC-HUS) and genetic defect in cobalamin C metabolism. Two patients were excluded from the full analysis set due to a confirmed diagnosis of STEC-HUS. Ninety-three percent of patients had extra renal signs (cardiovascular, pulmonary, central nervous system, gastrointestinal, skin, skeletal muscle) or symptoms of aHUS at baseline. Table 10 presents the demographics and baseline characteristics of the 56 adult patients enrolled in Study ALXN1210‑aHUS‑311 that constituted the full analysis set. Table 10: Baseline characteristics in the adult study Parameter Statistics Ravulizumab (N = 56) Age at time of first infusion (years) Mean (SD) Min, max 42.2 (14.98) 19.5, 76.6 Sex Male n (%) 19 (33.9) Race Asian White Unknown/other n (%) 15 (26.8) 29 (51.8) 12 (21.4) History of transplant n (%) 8 (14.3) Platelets (10 9 /L) blood n Median (min,max) 56 95.25 (18, 473) Haemoglobin (g/L) blood n Median (min,max) 56 85.00 (60.5, 140) LDH (U/L) serum n Median (min,max) 56 508.00 (229.5, 3249) eGFR (mL/min/1.73 m 2 ) n (%) Median (min,max) 55 10.00 (4, 80) Patients on dialysis N (%) 29 ( 51.8) Patients post partum N (%) 8 (14.3) Note: Percentages are based on the total number of patients. Abbreviations: eGFR = estimated glomerular filtration rate; LDH = lactate dehydrogenase; max = maximum; min = minimum. The primary endpoint was Complete TMA Response during the 26-week Initial Evaluation Period, as evidenced by normalisation of haematological parameters (platelet count ≥ 150 x 10 9 /L and LDH ≤ 246 U/L) and ≥ 25% improvement in serum creatinine from baseline. Patients had to meet each Complete TMA Response criteria at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between. Complete TMA Response was observed in 30 of the 56 patients (53.6%) during the 26-week initial evaluation period as shown in Table 11. Table 11: Complete TMA response and complete TMA response components analysis for the 26-week initial evaluation period (ALXN1210-aHUS-311) Total Responder n Proportion (95% CI) a Complete TMA Response 56 30 0.536 (0.396, 0.675) Components of Complete TMA Response Platelet count normalisation LDH normalisation ≥25% improvement in serum creatinine from baseline 56 56 56 47 43 33 0.839 (0.734, 0.944) 0.768 (0.648, 0.887) 0.589 (0.452, 0.727) Haematologic normalisation 56 41 0.732 (0.607, 0.857) a 95 % CIs for the proportion were based on the asymptotic Gaussian approximation method with a continuity correction. Abbreviations: CI = confidence interval; LDH = lactate dehydrogenase; TMA = thrombotic microangiopathy. Complete TMA Response was observed in six additional patients during the extension period at Days 169, 302, 401,407, 1247 and 1359 resulting in an overall Complete TMA Response in 36 of 56 patients (64.3%; 95% CI: 50.8%, 77.7%) through end of study. Individual component response increased to 48 (85.7%; 95% CI: 75.7%, 95.8%) patients for platelet count normalisation, 49 (87.5%; 95% CI: 77.9%, 97.1%) patients for LDH normalisation, and 37 (66.1%; 95% CI: 52.8%, 79.4%) patients for renal function improvement. The median time to Complete TMA Response was 86 days (7 to 1359 days). A rapid increase in mean platelet count was observed after commencement of ravulizumab, increasing from 118.52 × 10 9 /L at baseline to 243.54 × 10 9 /L at Day 8 and remaining above 227 × 10 9 /L at all subsequent visits in the initial evaluation period (26 weeks). Similarly, mean LDH value decreased from baseline over the first 2 months of treatment and was sustained over the duration of the initial evaluation period (26 weeks). Over two thirds of the patient population who were mostly CKD Stage 4 or 5 at baseline improved by 1 or more CKD stages by Day 743 of study. Improvement in renal function as measured by eGFR continued to be stable through end of study. Chronic kidney disease stage continued to improve for many patients (19/30) after achieving Complete TMA Response during the 26-week initial evaluation period. Of the 27 patients who did not require dialysis at study entry, 19 patients remained off dialysis during the entire study period and 8 patients initiated dialysis during the study, with 2 of these patients discontinuing dialysis during the study. One of the patients that discontinued dialysis during the extension study period, then reinitiated dialysis and continued through study completion. Table 12: Secondary efficacy outcome for the 26-Week Initial Evaluation Period of study ALXN1210‑aHUS‑311 Parameters Study ALXN1210‑aHUS‑311 (N = 56) Haematologic TMA parameters, Day 183 Platelets (10 9 /L) blood Mean (SD) Median LDH (U/L) serum Mean (SD) Median Observed value (n=48) 237.96 (73.528) 232.00 194.46 (58.099) 176.50 Change from baseline (n=48) 114.79 (105.568) 125.00 -519.83 (572.467) -310.75 Increase in haemoglobin of ≥ 20 g/L from baseline with a confirmatory result through Initial Evaluation Period n/m proportion (95% CI)* 40/56 0.714 (0.587, 0.842) CKD stage shift from baseline, Day 183 Improved a n/m Proportion (95% CI)* Worsened b n/m Proportion (95% CI)* 32/47 0.681 (0.529, 0.809) 2/13 0.154 (0.019, 0.454) eGFR (mL/min/1.73 m 2 ), Day 183 Mean (SD) Median Observed value (n=48) 51.83 (39.162) 40.00 Change from baseline (n=47) 34.80 (35.454) 29.00 Note: n: number of patients with available data for specific assessment at Day 183 visit. m: number of patients meeting specific criterion. Chronic kidney disease (CKD) stage is classified based on the National Kidney Foundation Chronic Kidney Disease Stage. Stage 5 is considered the worst category, while Stage 1 is considered the best category. Baseline is derived based on the last available eGFR before starting treatment. Improved/Worsened: compared to CKD stage at baseline. *95% confidence intervals (95% CIs) are based on exact confidence limits using the Clopper‑Pearson method. a Excludes those with CKD Stage 1 at baseline as they cannot improve. b Excludes patients with Stage 5 at baseline as they cannot worsen. Abbreviations: eGFR = estimated glomerular filtration rate; LDH = lactate dehydrogenase; TMA = thrombotic microangiopathy. The final efficacy analysis for the study on all patients treated with ravulizumab over a median treatment duration of 130.36 weeks confirmed that ravulizumab treatment responses observed during the Primary Evaluation Period were maintained throughout the duration of the study. Generalised Myasthenia Gravis (gMG) Study in adult patients with gMG The efficacy and safety of ravulizumab in adult patients with gMG was assessed in a Phase 3, randomised, double-blind, placebo-controlled, multicentre study (ALXN1210-MG-306). Patients participating in this study were subsequently allowed to enter an Open-Label Extension Period during which all patients received ravulizumab. Patients with gMG (diagnosed for at least 6 months) with a positive serologic test for anti-acetylcholine receptor (AChR) antibodies, MGFA (Myasthenia Gravis Foundation of America) clinical classification Class II to IV and remaining symptomatology as evidenced by a Myasthenia Gravis Activities of Daily Living (MG-ADL) total score ≥ 6 were randomised to receive either ravulizumab (N = 86) or placebo (N = 89). Patients on immunosuppressant therapies (corticosteroids, azathioprine, cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, or tacrolimus) were permitted to continue on therapy throughout the course of the study. In addition, rescue therapy (including high dose corticosteroid, PE/PP, or IVIg) was allowed if a patient experienced clinical deterioration, as defined by the study protocol. A total of 162 (92.6%) patients completed the 26-week Randomised-Controlled Period of Study ALXN1210-MG-306. The baseline characteristics of patients are presented in Table 13. The majority (97%) of patients included in the study had been treated with at least one immunomodulatory therapy including immunosuppressant therapies, PE/PP, or IVIg in the last two years prior to enrolment. Table 13: Baseline disease characteristics in study ALXN1210-MG-306 Parameter Statistics Placebo (N = 89) Ravulizumab (N = 86) Sex Male Female n (%) 44 (49.4) 45 (50.6) 42 (48.8) 44 (51.2) Age at first dose of study drug (years) Mean (SD) (min, max) 53.3 (16.05) (20, 82) 58.0 (13.82) (19, 79) Elderly (≥ 65 years of age) at study entry n (%) 24 (27.0) 30 (34.9) Duration of MG since diagnosis (years) Mean (SD) (min, max) Median 10.0 (8.90) (0.5, 36.1) 7.6 9.8 (9.68) (0.5, 39.5) 5.7 Baseline MG-ADL Score Mean (SD) (min, max) Median 8.9 (2.30) (6.0, 15.0) 9.0 9.1 (2.62) (6.0, 24.0) 9.0 Baseline QMG Score Mean (SD) (min, max) Median 14.5 (5.26) (2.0, 27.0) 14.0 14.8 (5.21) (6.0, 39.0) 15.0 Baseline MGFA classification Class II (mild weakness) Class III (moderate weakness) Class IV (severe weakness) n (%) 39 (44) 45 (51) 5 (6) 39 (45) 41 (48) 6 (7) Any prior intubation since diagnosis (MGFA Class V) n (%) 9 (10.1) 8 (9.3) Number of patients with prior MG crisis since diagnosis a n (%) 17 (19.1) 21 (24.4) Number of stable immunosuppressant therapies b at study entry 0 1 ≥ 2 n (%) 8 (9.0) 34 (38.2) 47 (52.8) 10 (11.6) 40 (46.5) 36 (41.9) a Prior MG crisis information was collected as part of medical history and not evaluated as per the clinical protocol definition. b Immunosuppressant therapies include corticosteroids, azathioprine, cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, or tacrolimus. Abbreviations: Max = maximum; min = minimum; MG = myasthenia gravis; MG-ADL = Myasthenia Gravis Activities of Daily Living; MGFA = Myasthenia Gravis Foundation of America; QMG = Quantitative Myasthenia Gravis; SD = standard deviation The primary endpoint was the change from Baseline to Week 26 in the MG-ADL total score. The secondary endpoints, also assessing changes from Baseline to Week 26, included the change in the Quantitative Myasthenia Gravis (QMG) total score, the proportion of patients with improvements of at least 5 and 3 points in the QMG and MG-ADL total scores, respectively, as well as changes in quality‑of‑life assessments. Ravulizumab demonstrated a statistically significant change in the MG‑ADL total score as compared to placebo. Primary and secondary endpoint results are presented in Table 14. Table 14: Analysis of primary and secondary efficacy endpoints Efficacy Endpoints at Week 26 Placebo (N = 89) LS Mean (SEM) Ravulizumab (N = 86) LS Mean (SEM) Statistic for Comparison Treatment Effect (95% CI) p-value (Using Mixed Effect Repeated Measures) MG-ADL -1.4 (0.37) -3.1 (0.38) Difference in change from baseline -1.6 (-2.6, -0.7) 0.0009 QMG -0.8 (0.45) -2.8 (0.46) Difference in change from baseline -2.0 (-3.2, -0.8) 0.0009 MG-QoL15r -1.6 (0.70) -3.3 (0.71) Difference in change from baseline -1.7 (-3.4, 0.1) 0.0636 Neuro‑QoL‑fatigue -4.8 (1.87) -7.0 (1.92) Difference in change from baseline -2.2 (-6.9, 2.6) 0.3734 a a The endpoint was not formally tested for statistical significance; a nominal p-value was reported. Abbreviations: CI = confidence interval; LS = least squares; MG-ADL = Myasthenia Gravis Activities of Daily Living; MG-QoL15r = Revised Myasthenia Gravis Quality of Life 15‑item scale; Neuro-QoL-fatigue = Neurological Quality of Life Fatigue; QMG = Quantitative Myasthenia Gravis; SEM = standard error of mean. In Study ALXN1210-MG-306, a clinical responder in the MG-ADL total score was defined as having at least a 3-point improvement. The proportion of clinical responders at Week 26 was 56.7% on ravulizumab compared with 34.1% on placebo (nominal p=0.0049). A clinical responder in the QMG total score was defined as having at least a 5-point improvement. The proportion of clinical responders at Week 26 was 30.0% on ravulizumab compared with 11.3% on placebo (p=0.0052). Table 15 presents an overview of the patients with clinical deterioration and patients requiring rescue therapy over the 26-week Randomised-Controlled Period. Table 15: Clinical deterioration and rescue therapy Variable Statistic Placebo (N = 89) Ravulizumab (N = 86) Total number of patients with clinical deterioration n (%) 15 (16.9) 8 (9.3) Total number of patients requiring rescue therapy a n (%) 14 (15.7) 8 (9.3) a Rescue therapy included high-dose corticosteroid, plasma exchange/plasmapheresis, or intravenous immunoglobulin. In patients who initially received Ultomiris during the Randomised-Controlled Period and continued to receive Ultomiris up to 164-weeks of the Open-Label Extension Period, the treatment effect continued to be sustained (Figure 3). In patients who initially received placebo during the 26-week Randomised-Controlled Period and initiated treatment with Ultomiris during the Open-Label Extension Period, a rapid and sustained treatment response on all endpoints including MG-ADL and QMG (Figure 3), was observed over a median treatment duration of approximately 2 years. Figure 3: Change from randomised-controlled period baseline in MG-ADL total score (A) and QMG total score (B) up to week 164 (mean and 95% CI) Note: Randomized Controlled Period figures are based on data from 175 patients. Open Label Extension Period figures are based on data from 161 patients. Abbreviations: CI = confidence interval; MG-ADL = Myasthenia Gravis Activities of Daily Living; QMG = Quantitative Myasthenia Gravis In the Open-Label Extension Period of the study, clinicians had the option to adjust immunosuppressant therapies. At the end of the Open-Label Extension Period (median duration of Ultomiris treatment both during Randomised-Control Period and Open-Label Extension was 759 days), 30.1% of patients decreased their daily dose of corticosteroid therapy and 12.4% of patients stopped corticosteroid therapy. The most common reason for change in corticosteroid therapies was improvement in MG symptoms while on ravulizumab treatment. Neuromyelitis Optica Spectrum Disorder (NMOSD) Study in adult patients with NMOSD The efficacy of ravulizumab in adult patients with anti-AQP4 antibody-positive NMOSD was assessed in a global, open-label clinical study (ALXN1210-NMO-307). Study ALXN1210-NMO-307 enrolled 58 adult patients with NMOSD who had a positive serologic test for anti-AQP4 antibodies, at least 1 relapse in the last 12 months prior to the Screening Period, and an Expanded Disability Status Scale (EDSS) score of ≤ 7. Prior treatment with immunosuppressant therapies (ISTs) was not required for enrolment and 53.4% of patients were on ravulizumab monotherapy. Patients on selected ISTs (i.e., corticosteroids, azathioprine, mycophenolate mofetil, tacrolimus) were permitted to continue on therapy in combination with ravulizumab, with a requirement for stable dosing until they reached Week 106 in the study. In addition, acute therapy for relapse treatment (including high-dose corticosteroids, PE/PP, and IVIg) was allowed if a patient experienced a relapse during the study. Patients included in the study had a mean age of 47.4 years (ranging from 18 to 74 years) and most of them were female (90%). Median age at NMOSD initial clinical presentation was of 42.5 years, ranging from 16 to 73 years. Baseline disease characteristics are shown in Table 16. Table 16: Patient disease history and baseline characteristics in study ALXN1210-NMO-307 Variable Statistic ALXN1210-NMO-307 Ravulizumab (N = 58) Time from NMOSD initial clinical presentation to first dose of study drug (years) Mean (SD) 5.2 (6.38) Median 2.0 Min, max 0.19, 24.49 Historical ARR within 24 months prior to screening Mean (SD) 1.87 (1.59) Median 1.44 Min, max 0.5, 6.9 Baseline HAI score Mean (SD) 1.2 (1.42) Median 1.0 Min, max 0, 7 Baseline EDSS score Mean (SD) 3.30 (1.58) Median 3.25 Min, max 0.0, 7.0 Any historical rituximab use n (%) 21 (36.2) Number of patients receiving stable corticosteroids only at study entry n (%) 11 (19.0) Number of patients not receiving any IST at study entry n (%) 31 (53.4) Abbreviations: ARR = annualised relapse rate; EDSS = Expanded Disability Status Scale; HAI = Hauser Ambulation Index; IST = immunosuppressant therapy; Max = maximum; Min = minimum; NMOSD = neuromyelitis optica spectrum disorder; SD = standard deviation. The primary endpoint of Study ALXN1210-NMO-307 was the time to first adjudicated on-trial relapse as determined by an independent adjudication committee. No adjudicated on-trial relapse was observed in ravulizumab-treated patients during the primary treatment period. All ravulizumab-treated patients remained relapse free over the median follow-up of 90.93 weeks. Ravulizumab-treated patients experienced consistent relapse-free primary endpoint result with or without concomitant IST treatment. In the final efficacy analysis with median follow up of 170.29 weeks, no adjudicated on-trial relapses were observed in ravulizumab treated patients through the end of study. Ravulizumab treatment responses observed during the Primary Evaluation Period were maintained throughout the duration of the study. In addition, among the 27 patients on IST treatment at Baseline, 17 (63%) had a decrease or stopped at least one IST therapy during treatment with ravulizumab. Ravulizumab has not been studied for the acute treatment of relapses in NMOSD patients. Paediatric population Paroxysmal nocturnal haemoglobinuria (PNH) Study in paediatric patients with PNH (ALXN1210-PNH-304) The paediatric study (ALXN1210-PNH-304) is a multicentre, open-label, Phase 3 study conducted in eculizumab-experienced and complement inhibitor-naïve paediatric patients with PNH. From interim results, a total of 13 PNH paediatric patients completed ravulizumab treatment during the primary evaluation period (26 weeks) of Study ALXN1210-PNH-304. Five of the 13 patients had never been treated with a complement inhibitor and 8 patients received treatment with eculizumab prior to study entry. Most of the patients were between 12 years and 17 years of age at first infusion (mean: 14.4 years), with 2 patients under 12 years old (11 years and 9 years old). Eight of the 13 patients were female. Mean weight at baseline was 56 kg, ranging from 37 to 72 kg. Table 17 presents the baseline disease history and characteristics of the paediatric patients enrolled in Study ALXN1210‑PNH-304. Table 17: Disease history and characteristics at baseline (full analysis set) Variable Complement inhibitor-naïve patients (N = 5) Eculizumab-experienced patients (N = 8) Total PNH RBC clone size (%) Median (min, max) (N = 4) 40.05 (6.9, 68.1) (N = 6) 71.15 (21.2, 85.4) Total PNH granulocyte clone size (%) Median (Min, max) 78.30 (36.8, 99.0) 91.60 (20.3, 97.6) Number of patients with pRBC/whole blood transfusions within 12 months prior to first dose, n (%) 2 (40.0) 2 (25.0) Number of pRBC/whole blood transfusions within 12 months prior to first dose Total Median (min, max) 10 5.0 (4, 6) 2 1.0 (1, 1) Units of pRBC/whole blood transfused within 12 months prior to first dose Total Median (min, max) 14 7.0 (3, 11) 2 2.0 (2, 2) Patients with any PNH-associated conditions prior to informed consent, n (%) Anaemia Haematuria or haemoglobinuria Aplastic anaemia Renal failure Other a 5 (100) 2 (40.0) 2 (40.0) 3 (60.0) 2 (40.0) 0 8 (100) 5 (62.5) 5 (62.5) 1 (12.5) 2 (25.0) 1 (12.5) Pre-treatment LDH levels (U/L) Median (min, max) 588.50 (444, 2269.7) 251.50 (140.5, 487) a Other PNH-associated conditions were reported as “renal and splenic infarcts” and “multiple lesions concerning for embolic process”. Note: Percentages were based on the total number of patients in each cohort. Abbreviations: LDH = lactate dehydrogenase; max = maximum; min = minimum; PNH = paroxysmal nocturnal haemoglobinuria; pRBC = packed red blood cell; RBC = red blood cell. Based on body weight, patients received a loading dose of ravulizumab on Day 1, followed by maintenance treatment on Day 15 and once every 8 weeks (q8w) thereafter for patients weighing ≥ 20 kg, or once every 4 weeks (q4w) for patients weighing < 20 kg. For patients who entered the study on eculizumab therapy, Day 1 of study treatment was planned to occur 2 weeks from the patient's last dose of eculizumab. The weight-based dose regimen of ravulizumab provided immediate, complete, and sustained inhibition of terminal complement throughout the 26-week primary evaluation period regardless of prior experience with eculizumab. Following initiation of ravulizumab treatment, steady-state therapeutic serum concentrations of ravulizumab were achieved immediately after the first dose and maintained throughout the 26-week primary evaluation period in both cohorts. There were no breakthrough haemolysis events in the study and no patients had post-baseline free C5 levels above 0.5 µg/mL. Mean percent change from baseline in LDH was -47.91% on Day 183 in the complement inhibitor-naïve cohort and remained stable in the eculizumab-experienced cohort during the 26‑week primary evaluation period. Sixty percent (3/5) of complement inhibitor-naïve patients and 75% (6/8) of eculizumab-experienced patients achieved haemoglobin stabilisation by Week 26 respectively. Transfusion-avoidance was reached by 84.6% (11/13) of patients during the 26-week primary evaluation period. These interim efficacy results are presented in Table 18 below. Table 18: Efficacy outcomes from the paediatric study in PNH patients (ALXN1210-PNH-304) - 26-week primary evaluation period End Point Ravulizumab (Naïve, N = 5) Ravulizumab (Switch, N = 8) LDH- Percent change from Baseline Mean (SD) -47.91 (52.716) 4.65 (44.702) Transfusion Avoidance Percentage (95% CI) 60.0 (14.66, 94.73) 100.0 (63.06, 100.00) Haemoglobin Stabilisation Percentage (95% CI) 60.0 (14.66, 94.73) 75 (34.91, 96.81) Breakthrough Haemolysis (%) 0 0 Abbreviations: LDH = lactate dehydrogenase Long term efficacy results through end of study over a median treatment duration of 915 days resulted in a sustained treatment response in paediatric patients with PNH. Based on data from these interim results, the efficacy of ravulizumab in paediatric PNH patients appears to be similar to that observed in adult PNH patients. Atypical haemolytic uremic syndrome (aHUS) Use of Ultomiris in paediatric patients for treatment of aHUS is supported by evidence from one paediatric clinical study (a total of 31 patients with documented aHUS were enrolled; 28 patients aged 10 months to 17 years were included in the full analysis set). Study in paediatric patients with aHUS (ALXN1210 aHUS 312) The paediatric study was a 26-week, multicentre, single arm, Phase 3 study conducted in paediatric patients and patients were allowed to enter an extension period for up to 4.5 years. A total of 24 eculizumab-naïve patients with documented diagnosis of aHUS and evidence of TMA were enrolled, of which 20 were included in the Full Analysis set. Enrolment criteria excluded patients presenting with TMA due to a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency, STEC-HUS and genetic defect in cobalamin C metabolism. Four patients were given 1 or 2 doses, but then discontinued and were excluded from the full analysis set because aHUS eligibility was not confirmed. The overall mean weight at baseline was 21.2 kg; majority of the patients were in the baseline weight category ≥ 10 to < 20 kg. The majority of patients (70.0%) had pretreatment extra renal signs (cardiovascular, pulmonary, central nervous system, gastrointestinal, skin, skeletal muscle) or symptoms of aHUS at baseline. At baseline, 35.0% (n = 7) of patients had CKD Stage 5. A total of 10 patients, who switched from eculizumab to ravulizumab, had documented diagnosis of aHUS and evidence of TMA were enrolled. Patients had to have clinical response to eculizumab prior to enrolment (i.e. LDH < 1.5 X ULN and platelet count ≥ 150,000/μL, and eGFR > 30 mL/min/1.73 m 2 ). Consequently, there is no information on the use of ravulizumab in patient refractory to eculizumab. Table 19 presents the baseline characteristics of the paediatric patients enrolled in Study ALXN1210‑aHUS-312. Table 19: Demographics and baseline characteristics in study ALXN1210‑aHUS‑312 Parameter Statistics Ravulizumab (Naïve, N = 20) Ravulizumab (Switch, N = 10) Age at time of first infusion (years) category Birth to < 2 years 2 to < 6 years 6 to < 12 years 12 to < 18 years n (%) 4 (20.0) 9 (45.0) 5 (25.0) 2 (10.0) 1 (10.0) 1 (10.0) 1 (10.0) 7 (70.0) Sex Male n (%) 8 (40.0) 9 (90.0) Race a American Indian or Alaskan Native Asian Black or African American White Unknown n (%) 1 (5.0) 5 (25.0) 3 (15.0) 11 (55.0) 1 (5.0) 0 (0.0) 4 (40.0) 1 (10.0) 5 (50.0) 0 (0.0) History of transplant n (%) 1 (5.6) 1 (10.0) Platelets (10 9 /L) blood Median (min, max) 51.25 (14, 125) 281.75 (207, 415.5) Haemoglobin (g/L) Median (min, max) 74.25 (32, 106) 132.0 (114.5, 148) LDH (U/L) Median (min, max) 1963.0 (772, 4985) 206.5 (138.5, 356) eGFR (mL/min/1.73 m 2 ) Median (min, max) 22.0 (10, 84) 99.75 (54, 136.5) Required dialysis at baseline n (%) 7 (35.0) 0 (0.0) Note: Percentages are based on the total number of patients. a Patients can have multiple races selected. Abbreviations: eGFR = estimated glomerular filtration rate; LDH = lactate dehydrogenase; max = maximum; min = minimum. The primary endpoint was Complete TMA Response during the 26-week Initial Evaluation Period, as evidenced by normalisation of haematological parameters (platelet ≥ 150 x 10 9 /L and LDH ≤ 246 U/L) and ≥ 25% improvement in serum creatinine from baseline in eculizumab-naïve patients. Patients had to meet all Complete TMA Response criteria at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between. Complete TMA Response was observed in 15 of the 20 naïve patients (75.0%) during the 26-week initial evaluation period as shown in Table 20. Table 20: Complete TMA response and complete TMA response components analysis during the 26-week initial evaluation period (ALXN1210-aHUS-312) Total Responder n Proportion (95% CI) a Complete TMA Response 20 15 0.750 (0.509, 0.913) Components of Complete TMA Response Platelet count normalisation LDH normalisation ≥ 25% improvement in serum creatinine from baseline 20 20 20 19 18 16 0.950 (0.751, 0.999) 0.900 (0.683, 0.988) 0.800 (0.563, 0.943) Haematologic normalisation 20 18 0.900 (0.683, 0.988) a 95% CIs for the proportion were based on the asymptotic Gaussian approximation method with a continuity correction. Abbreviations: CI = confidence interval; LDH = lactate dehydrogenase; TMA = thrombotic microangiopathy. Complete TMA Response during the initial evaluation period was achieved at a median time of 30 days (15 to 99 days). All patients with Complete TMA Response maintained it through the initial evaluation period with continuous improvements seen in renal function. An increase in mean platelet count was observed rapidly after commencement of ravulizumab, increasing from 71.70 × 10 9 /L at baseline to 302.41 × 10 9 /L at Day 8 and remained above 304 × 10 9 /L at all subsequent visits after Day 22 in the initial evaluation period (26 weeks). Complete TMA Response was observed in three additional patients during the Extension Period at Days 295 for 2 patients and Day 351 for 1 patient) resulting in the achievement of Complete TMA response in 18 of 20 paediatric patients (90%; 95% CI: 68.3%, 98.8%) through end of study. Individual component response increased to 19 of 20 (95.0%; 95% CI: 75.1%, 99.9%) patients for platelet count normalisation, 19 of 20 (95.0%; 95% CI: 75.1%, 99.9%) patients for LDH normalisation, and in 18 of 20 (90.0%; 95% CI: 68.3%, 98.8%) patients for renal function improvement. All 7 of the patients who required dialysis at study entry were able to discontinue dialysis; 6 of which had already done so by Day 36. No patient started or re-initiated dialysis during the study. For the 16 patients with available baseline and Week 52 (Day 351) data, 16 patients had improvement in chronic kidney disease (CKD) stage compared with baseline. Patients with available data through the end of the study continued to have improvements or no changes in CKD stage. Improvement in renal function as measured by eGFR continued to be stable through end of study. Table 21 summarises the secondary efficacy results for Study ALXN1210‑aHUS‑312. Table 21: Secondary efficacy outcome for the 26-Week Initial Evaluation Period for study ALXN1210‑aHUS‑312 Parameters Study ALXN1210‑aHUS‑312 (N = 20) Haematologic TMA parameters, Day 183 Platelets (10 9 /L) blood Mean (SD) Median LDH (U/L) serum Mean (SD) Median Observed value (n = 17) 304.94 (75.711) 318.00 262.41 (59.995) 247.00 Change from baseline (n = 17) 245.59 (91.827) 247.00 -2044.13 (1328.059) -1851.50 Increase in haemoglobin of ≥ 20 g/L from baseline with a confirmatory result through Initial Evaluation Period n/m proportion (95% CI)* 17/20 0.850 (0.621, 0.968) CKD stage shift from baseline, Day 183 Improved a n/m Proportion (95% CI)* Worsened b n/m Proportion (95% CI)* 15/17 0.882 (0.636, 0.985) 0/11 0.000 (0.000, 0.285) eGFR (mL/min/1.73 m 2 ), Day 183 Mean (SD) Median Observed value (n = 17) 108.5 (56.87) 108.0 Change from baseline (n = 17) 85.4 (54.33) 80.0 Note: n: number of patients with available data for specific assessment at Day 183 visit. m: number of patients meeting specific criterion. Chronic kidney disease (CKD) stage is classified based on the National Kidney Foundation Chronic Kidney Disease Stage. Stage 1 is considered the best category, while Stage 5 is considered the worst category. Baseline is derived based on the last available eGFR before starting treatment. Improved/Worsened: Compared to CKD stage at baseline. *95% confidence intervals (95% CIs) are based on exact confidence limits using the Clopper Pearson method. a Improved excludes patients with Stage 1 at baseline, as they cannot improve; b worsened excludes patients with Stage 5 at baseline as they cannot worsen. Abbreviations: eGFR = estimated glomerular filtration rate; LDH = lactate dehydrogenase; TMA = thrombotic microangiopathy. In eculizumab-experienced patients, switching to ravulizumab maintained disease control as evidenced by stable hematologic and renal parameters, with no apparent impact on safety. The efficacy of ravulizumab for the treatment of aHUS appears similar in paediatric and adult patients. The final efficacy analysis for the study on all paediatric patients treated with ravulizumab over a median treatment duration of 130.60 weeks confirmed that ravulizumab treatment responses observed during the Primary Evaluation Period were maintained throughout the duration of the study. Generalised myasthenia gravis (gMG) The European Medicines Agency has deferred the obligation to submit the results of studies with Ultomiris in one or more subsets of the paediatric population in the treatment of myasthenia gravis. See 4.2 for information on paediatric use. Neuromyelitis optica spectrum disorder (NMOSD) The European Medicines Agency has deferred the obligation to submit the results of studies with Ultomiris in one or more subsets of the paediatric population in the treatment of NMOSD. See 4.2 for information on paediatric use.